Human recombinant chromogranin A-derived vasostatin-1 mimics preconditioning via an adenosine/nitric oxide signaling mechanism - Wikidata - wikimedia - TriplyDB

Human recombinant chromogranin A-derived vasostatin-1 mimics preconditioning via an adenosine/nitric oxide signaling mechanism

Human recombinant chromogranin A-derived vasostatin-1 mimics preconditioning via an adenosine/nitric oxide signaling mechanism

http://www.wikidata.org/entity/Q57950968

about

The novel chromogranin A-derived serpinin and pyroglutaminated serpinin peptides are positive cardiac β-adrenergic-like inotropes Human catestatin peptides differentially regulate infarct size in the ischemic-reperfused rat heart Mass spectrometry-based neuropeptidomics of secretory vesicles from human adrenal medullary pheochromocytoma reveals novel peptide products of prohormone processing Catestatin improves post-ischemic left ventricular function and decreases ischemia/reperfusion injury in heart.pGlu-serpinin protects the normotensive and hypertensive heart from ischemic injury Serpinins: role in granule biogenesis, inhibition of cell death and cardiac function.Catestatin (chromogranin A344-364) is a novel cardiosuppressive agent: inhibition of isoproterenol and endothelin signaling in the frog heart.The antihypertensive chromogranin a peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism Platelet activating factor: the good and the bad in the ischemic/reperfused heart.Redox balance and cardioprotection.The surging role of Chromogranin A in cardiovascular homeostasis.Chromogranin A: a paradoxical player in angiogenesis and vascular biology.Nesfatin-1: a new energy-regulating peptide with pleiotropic functions. Implications at cardiovascular level.Catestatin reduces myocardial ischaemia/reperfusion injury: involvement of PI3K/Akt, PKCs, mitochondrial KATP channels and ROS signalling.Overexpression of vasostatin-1 protects hypoxia/reoxygenation injuries in cardiomyocytes independent of endothelial cells.Apelin-13 limits infarct size and improves cardiac postischemic mechanical recovery only if given after ischemia.Glycosylated Chromogranin A: Potential Role in the Pathogenesis of Heart Failure.Chromogranins: from discovery to current times.Vasostatin-1 Stops Structural Remodeling and Improves Calcium Handling via the eNOS-NO-PKG Pathway in Rat Hearts Subjected to Chronic β-Adrenergic Receptor Activation.Nesfatin-1 as a novel cardiac peptide: identification, functional characterization, and protection against ischemia/reperfusion injury.Increased N-terminal CgA in circulation associated with cardiac reperfusion in pigs.

P2860

Q28579371-04937DE1-4AC3-4276-B0FB-FA85327D7E81 Q34388245-915A5582-3B42-4930-B6B6-0461240D4767 Q34397442-0B3022A9-8DB0-44DC-8E63-081CC912AD29 Q34435168-B6055AED-51DB-41D5-B8E3-B1F4786590BA Q36296309-AB502FE6-DE4C-469B-80E3-C267AE4A2E55 Q36781898-804CE318-E531-4807-AE45-02A651D284C9 Q36807907-1E21C2E9-4ABC-4246-80D2-2DAC372A6A5D Q36972684-20ED6EAF-D1B7-4F39-B2A4-83F570F983CD Q37850200-AB92BF76-9DEE-46B5-8233-C10F8AAC4231 Q38155452-1D7ABBE7-DB2C-4813-B7C5-1555F6E3C0C4 Q38245248-AE7A2D23-8C55-4612-94DB-6CFC883EC2BE Q38258283-18602B5E-0535-4D1A-AC7F-CBD21C44C4C6 Q38667872-BFC69171-CC09-4457-A930-79A12DA2E5BC Q39210583-F8CC063C-9A4A-49C5-8A53-D25CEE3F8E70 Q39711721-EB891372-E889-4B79-A972-C9E4FA6477B1 Q47387978-C12EE115-8C09-4AEE-B67D-FC0E581C0664 Q47702359-A5E99DC1-859F-4677-95AA-5D4BF595CFA5 Q47712415-9705B4CF-36DB-4487-AC1B-121A3A8BAF9D Q51533381-A15B888F-7A3F-46BC-9CB6-BE5472704A42 Q54485726-335234EB-D014-4689-8158-60C30F70D4A7 Q54549853-B77C0630-7047-4BEA-A3EE-1FB156A3932B

P2860

Human recombinant chromogranin A-derived vasostatin-1 mimics preconditioning via an adenosine/nitric oxide signaling mechanism

http://www.wikidata.org/entity/Q57950968

description

im April 2007 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 06 April 2007

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в липні 2007

@uk

name

Human recombinant chromogranin ...... tric oxide signaling mechanism

@en

Human recombinant chromogranin ...... tric oxide signaling mechanism

@nl

type

label

Human recombinant chromogranin ...... tric oxide signaling mechanism

@en

Human recombinant chromogranin ...... tric oxide signaling mechanism

@nl

prefLabel

Human recombinant chromogranin ...... tric oxide signaling mechanism

@en

Human recombinant chromogranin ...... tric oxide signaling mechanism

@nl

P1433

Q57950968-C2836D41-CDA4-4934-86D0-5CAB5BFBF6A5

P1476

Q57950968-ED825D66-38DF-42D5-8BE0-F75010000707

P2093

Q57950968-2924862A-92A9-4620-8363-7AB0EB7E7FBC

Q57950968-46099232-153D-475A-9FA5-14A46CCFC3D4

Q57950968-5D6E675C-8050-4AE5-8FDE-5A154A5A4085

Q57950968-D20CB2EC-0409-41F4-A4E3-0C4578ABC93B

Q57950968-F9E8EF0B-C5E2-476B-BE9E-66C5ADD5FF21

P2860

Q57950968-050B1BFE-8AC4-4B8B-8A90-B8907CE7F4E6

Q57950968-097B4597-BE99-42F6-BFE8-561C2FB7F69E

Q57950968-0E727178-35A0-4DD4-9E88-A731547B0167

Q57950968-12554CDF-F115-4E14-915C-0CF760BF2545

Q57950968-21B0EC18-C37A-40AB-8D17-ACD35CEBFCE9

Q57950968-24E6CC5B-5B4C-4EC6-B6C6-DEBF69DA606F

Q57950968-36CB8CC6-83D5-451E-B4CF-E6FB65C7B38F

Q57950968-3DC685E6-AA7C-4D52-BE74-F7B18290681E

Q57950968-3EF6EFB2-77C4-492F-8B23-5385A27877AC

Q57950968-4479C877-F26F-4412-AD0B-21C36B23D0F2

P304

Q57950968-53655A96-CD5F-4781-890A-FC18CFA5BFBB

P31

Q57950968-4E42812D-F64C-4F05-AFCE-922FE3D10DF1

P356

Q57950968-EA856E74-8862-4EEF-8278-404DC497D073

P433

Q57950968-E13AD436-5BC7-4BF4-88E1-4F17CE4F68F7

P478

Q57950968-C8A39C1F-9E43-4064-98D3-519054EB81B5

P50

Q57950968-0693286D-1DB0-4356-83D2-3D3CD1234953

Q57950968-8C3D07D2-3D01-47EC-828D-ADCB59057FEC

Q57950968-E877C813-FEC1-4012-842A-2D3615B3D388

Q57950968-F42CBCDD-0509-40BB-AA96-6C1A30952546

P577

Q57950968-8583EC52-E5C5-4B7F-BB7F-E98A396207F4

P698

Q57950968-86279DE6-02EA-4C75-8E32-4D8DA9E195D3

P356

AJPHEART.01352.2006

P1433

American Journal of Physiology - Heart and Circulatory Physiology

P1476

Human recombinant chromogranin ...... tric oxide signaling mechanism

@en

P2093

Bruno Tota

http://www.w3.org/2001/XMLSchema#string

Claudia Penna

http://www.w3.org/2001/XMLSchema#string

Gianni Losano

http://www.w3.org/2001/XMLSchema#string

Sandra Cappello

http://www.w3.org/2001/XMLSchema#string

Tommaso Angelone

http://www.w3.org/2001/XMLSchema#string

P2860

Chromogranin A: current status as a precursor for bioactive peptides and a granulogenic/sorting factor in the regulated secretory pathway

Chromogranin A: its clinical value as marker of neuroendocrine tumours

G protein-mediated inhibitory effect of a nitric oxide donor on the L-type Ca2+ current in rat ventricular myocytes

Adenosine A2a blockade prevents synergy between mu-opiate and cannabinoid CB1 receptors and eliminates heroin-seeking behavior in addicted rats

Ischemic preconditioning: from adenosine receptor to KATP channel.

Preconditioning the myocardium: from cellular physiology to clinical cardiology.

Chromogranins: current concepts. Structural and functional aspects.

Cyclic AMP compartmentation due to increased cAMP-phosphodiesterase activity in transgenic mice with a cardiac-directed expression of the human adenylyl cyclase type 8 (AC8).

Ischemic preconditioning: from the first to the second window of protection.

Adenosine production and its interaction with protection of ischemic and reperfusion injury of the myocardium.

P304

H719-27

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1152/AJPHEART.01352.2006

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

293

http://www.w3.org/2001/XMLSchema#string

P50

Maria Carmela Cerra

Raffaella Rastaldo

Pasquale Pagliaro

P577

2007-04-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17416598

http://www.w3.org/2001/XMLSchema#string